Investor Relations
192
26
COMPOUNDS
TARGETS
66.7%
2
HIT RATE
PRECLINICAL LEAD-ASSETS
Featured
Model Medicines is proud to announce the publication of our first preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery," now available on bioRxiv.
// About Model Medicines
Innovating at the Intersection of Data Science, Biology and Drug Development
Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.
The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 192 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders.
The company is based in La Jolla, CA.
// AS FEATURED IN
// Papers
Featured
// Press Releases
Featured